Industry Q&A - Inside Cepheid Innovation: Women’s Health Portfolio

Friday, December 23, 2016 Published in January 2014 Written by Dr. David Persing, Chief Medical and Technology Officer, and Dr. Fred Weir, Director of Research and Development

Dr. David Persing and Dr. Fred Weir discuss the development of Xpert CT/NG, GBS LB and why these recently introduced tests are an important step in Cepheid’s plans for a complete line of Women’s Health diagnostic tests

Cost-effective Management of Clostridium difficile Infection—the Humanitas Experience

Friday, December 23, 2016 Published in January 2014 Written by Dr. Erminia Casari is Director at the Microbiology Laboratory of Humanitas Hospital in Milan, Italy and Professor of Microbiology at the Specializing School of Microbiology and Virology at University of Pavia

Clostridium difficile infection (CDI) is increasingly recognized as one of the most important healthcare associated infections throughout Europe, Canada and the United States.[1] The increasing incidence and severity has been attributed to the emergence of the hypervirulent strains PCR ribotypes 027 and 078 and the prevalence of CDI has risen from 3% to 13% [2, 3]. With the increasing infection rates from C. difficile, many recent studies have focused on the economic burden imposed by the management of CDI – notably, extended hospitalization, laboratory costs, and medical costs.[4]